Skip to main content

Latest news stories

Latest news stories

16-01-2019 | Rheumatoid arthritis | News

Gene expression profiling points to methotrexate nonresponders

Rheumatoid arthritis patients who are unlikely to respond to methotrexate could be identified based on their gene expression profiles before and 4 weeks after initiating treatment, say researchers.


Arthritis Rheum 2019; doi:10.1002/art.40810

15-01-2019 | ANCA-associated vasculitis | News

Randomized data back EULAR guidelines for mycophenolate mofetil use in AAV

Mycophenolate mofetil is noninferior to cyclophosphamide for inducing remission among patients with antineutrophil cytoplasmic antibody-associated vasculitis, randomized trial data show.


Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-214245

14-01-2019 | Rheumatoid arthritis | Highlight | News

Trial results support management of cardiovascular risk factors in RA patients

Managing traditional cardiovascular risk factors with a treat-to-target approach slows progression of subclinical atherosclerosis among patients with rheumatoid arthritis, suggest results from the FRANCIS trial.


Ann Rheum Dis 2019; doi:10.1136/annrheumdis-2018-214075

11-01-2019 | Juvenile idiopathic arthritis | News

News in brief

Predictors of outcomes identified in JIA-associated uveitis

Demographic factors, measures of disease activity, and the type of treatment used are associated with 2-year outcomes among patients with juvenile idiopathic arthritis-associated uveitis, according to findings from the ICON-JIA study.

10-01-2019 | Rheumatoid arthritis | News

Biologic combination therapy for RA may increase risk for side effects

Findings from a systematic review and meta-analysis suggest that rheumatoid arthritis patients who receive combination therapy with two biologic DMARDs are more likely to experience adverse events than those given one biologic.


Semin Arthritis Rheum 2018; doi:10.1016/j.semarthrit.2018.12.003

09-01-2019 | Rheumatoid arthritis | News

Serious infection risk similar among non-TNF inhibitor biologics in RA

Study findings do not support the use of one non-tumor necrosis factor inhibitor biologic DMARD over another when considering the risk for serious infection in patients with rheumatoid arthritis.


Ann Rhuem Dis 2018; doi:10.1136/annrheumdis-2018-214326

07-01-2019 | Rheumatoid arthritis | News

Abatacept associated with lower serious infection risk than TNF inhibitors

Rheumatoid arthritis patients who are treated with abatacept have a lower risk for hospitalization due to infection than those given tumor necrosis factor inhibitors, findings from a real-world study suggest.


Arthritis Care Res 2018; doi:10.1002/acr.23824

04-01-2019 | Osteoarthritis | News

News in brief

Payment program linked to reduced joint replacement spending

Implementation of a bundled-payment program has led to a “modest reduction” in spending on knee and hip replacement operations in the USA, say researchers.

03-01-2019 | Psoriatic arthritis | News

Support for methotrexate use in PsA patients

Findings from an observational study suggest that methotrexate treatment, with a dose-escalation strategy targeting remission, improves the joint and skin manifestations of psoriatic arthritis.


Rheumatology 2018; doi:10.1093/rheumatology/key369

02-01-2019 | Systemic lupus erythematosus | Highlight | News

Add-on omalizumab shows potential for SLE

Preliminary results from a phase Ib trial suggest that add-on treatment with the anti-IgE antibody omalizumab may be a feasible option for patients with systemic lupus erythematosus.


Arthritis Rheumatol 2018; doi:10.1002/art.40828

21-12-2018 | Osteoarthritis | Highlight | News

Long-term impact unclear for knee OA medications

Findings from a systematic review and network meta-analysis published in JAMA indicate that it is not clear whether pharmacologic treatments offer long-term benefits for patients with knee osteoarthritis.


JAMA 2018; 320: 2564–2579

20-12-2018 | Rheumatoid arthritis | Highlight | News

Serum calprotectin predicts relapse risk in TNFi-treated RA, PsA

Serum calprotectin levels independently predict relapse risk in tumor necrosis factor inhibitor-treated patients with rheumatoid arthritis or psoriatic arthritis who are in remission or have low disease activity, Spanish researchers report.


Arthritis Res Ther 2018; doi:10.1186/s13075-018-1764-z

19-12-2018 | Osteoarthritis | News

Targeting IL-1 ‘may not be effective’ for erosive hand OA

Findings from a randomized trial indicate that treatment with the interleukin-1α and -1β inhibitor lutikizumab does not improve pain or imaging outcomes among patients with erosive hand osteoarthritis.


Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213336

19-12-2018 | Psoriatic arthritis | News

News in brief

Abatacept may improve PROs in PsA patients

Treatment with abatacept is associated with improvements in patient-reported outcomes among individuals with psoriatic arthritis, study findings suggest.

17-12-2018 | Systemic lupus erythematosus | News

Lupus tied to increased cancer risk

Findings from a meta-analysis indicate that systemic lupus erythematosus is associated with an increased risk for 16 types of cancer.

14-12-2018 | Rheumatoid arthritis | News

Support for abatacept–methotrexate combination therapy in RA patients

Adding abatacept to methotrexate improves disease activity and reduces structural progression among ACPA-positive rheumatoid arthritis patients with early erosion, Japanese researchers report.


RMD Open 2018; 4: e000813

12-12-2018 | Gout | News

Hepatotoxicity reassurance for febuxostat-treated patients with gout and fatty liver disease

Results of an observational study provide preliminary evidence suggesting that patients with gout and fatty liver disease who are treated with febuxostat do not have an elevated risk for hepatotoxicity.


J Rheumatol 2018; doi:10.3899/jrheum.180761

10-12-2018 | Psoriatic arthritis | Highlight | News

ACR/NPF guidelines for the treatment of PsA published

The American College of Rheumatology and the National Psoriasis Foundation have issued evidence-based guidelines for the pharmacologic and nonpharmacologic treatment of active psoriatic arthritis.


Arthritis Rheumatol 2018; doi:10.1002/art.40726
Arthritis Care Res 2018; doi:10.1002/acr.23789
J Psoriasis Psoriatic Arthritis 2018; doi:10.1177/2475530318812244

06-12-2018 | Rheumatoid arthritis | News

Targeting B cells may delay RA development in those at risk

B-cell directed therapy with a single infusion of rituximab significantly delays the development of rheumatoid arthritis in people at high risk for developing the condition, exploratory study data show.


Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2017-212763

04-12-2018 | Ankylosing spondylitis | News

Elevated CRP levels may point to better secukinumab response in AS patients

Ankylosing spondylitis patients with elevated C-reactive protein levels may experience greater benefits from treatment with the interleukin-17A inhibitor secukinumab than those with lower levels of the inflammatory marker, researchers report.


RMD Open 2018; 4: e000749

image credits